dr. rini explains the axitinib integration process
Published 13 years ago • 166 plays • Length 0:38Download video MP4
Download video MP3
Similar videos
-
3:28
dr rini on a biomarker analysis for pembrolizumab/axitinib in advanced rcc
-
1:12
dr. rini describes axitinib's and sorafenib's side effects
-
2:16
dr. rini on axitinib for treatment of metastatic renal cell carcinoma
-
1:34
dr. rini on pembrolizumab plus axitinib in rcc
-
0:43
dr. rini discusses the vegf targeted agent axitinib
-
5:10
real-world treatment outcomes of 1l axitinib pembrolizumab in patients with advanced rcc in the us
-
6:36
mind/body insights into inflammation - nicabm
-
3:30
promising results for axitinib and pembrolizumab in advanced renal cell cancer
-
1:19
dr. rini on the efficacy of axitinib and pembrolizumab in rcc
-
1:03
dr. rini on managing the toxicity of pembrolizumab plus axitinib in mrcc
-
0:43
dr. rini on the results from his axitinib and sorafenib trial
-
0:49
dr. rini describes hypertension as a biomarker in rcc
-
0:44
dr. rini on the axitinib and sorafenib trial vegf focus
-
1:04
dr. rini discusses pembrolizumab plus axitinib in mrcc
-
0:45
dr. rini on the progression of advanced rcc therapy
-
0:53
dr. rini on standards of care for advanced rcc
-
9:52
phase 3 axitinib data in patients with previously treated advanced renal cell carcinoma
-
0:57
avelumab and axitinib for the treatment of advanced rcc
-
1:24
final results of avelumab and axitinib in rcc in the javelin renal 101 trial
-
4:07
tivo-3 results point to tivozanib activity after rcc progression on axitinib | brian rini
-
2:02
dr. mcgregor on implications of the fda approval of pembrolizumab/axitinib in rcc
-
1:17
dr. vaishampayan on axitinib plus pembrolizumab in advanced rcc